Lupin launches Tolvaptan tablets in the US for ADPKD treatment
By Aman Shukla Published on May 13, 2025, 12:00 IST
Lupin Limited, a global pharmaceutical company, has announced the launch of its generic Tolvaptan Tablets in the United States following approval from the U.S. Food and Drug Administration (FDA). The product is available in multiple strengths: 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg.
Tolvaptan Tablets are the generic equivalent of Jynarque®, a brand-name medication developed by Otsuka Pharmaceutical Company, Ltd. The drug is used to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
Lupin has secured exclusive first-to-file status for the generic version of Tolvaptan, which grants the company 180 days of marketing exclusivity in the U.S. market. This exclusivity period allows Lupin to be the only generic manufacturer selling the product during that time.
Vinita Gupta, CEO, Lupin, stated, 'We are pleased to announce the launch of Tolvaptan Tablets in the U.S. to provide ADPKD patients with increased access to high-quality treatment options.'
According to available data, Jynarque® recorded estimated U.S. sales of approximately $1.467 billion for the fiscal year ending December 31, 2024.
The launch of Tolvaptan Tablets is part of Lupin's strategy to expand its portfolio of affordable treatments in the U.S. pharmaceutical market.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Bajaj Auto June 2025 Sales: Company reports marginal 1% YoY growth to 3.6 lakh units
Bajaj Auto Limited posted a marginal 1% year-on-year (YoY) increase in total sales for June 2025, driven by strong export performance in both two-wheelers and commercial vehicles, even as domestic demand showed signs of weakness. June 2025 Sales Snapshot In June 2025, Bajaj Auto recorded total sales of 3,60,806 units, compared to 3,58,477 units in June 2024. While total two-wheeler sales declined slightly by 2% YoY to 2,98,484 units, strong momentum in the commercial vehicle (CV) segment — up 14% YoY to 62,322 units — helped offset the dip. Two-Wheelers Domestic : 1,49,317 units (down 16%) Exports : 1,49,167 units (up 18%) Commercial Vehicles Domestic : 39,143 units (up 69%) Exports : 23,179 units (up 49%) Overall domestic sales for the month came in at 1,88,460 units, marking a 13% YoY decline. However, exports surged 21% to 1,72,346 units, highlighting the company's growing international footprint. Q1 FY26 (April–June 2025) Performance For the April–June 2025 quarter, Bajaj Auto registered total sales of 11,11,237 units, a slight increase from 11,02,056 units in the same period last year. Two-Wheelers : Domestic : 5,29,344 units (down 9%) Exports : 4,19,447 units (up 14%) Commercial Vehicles : Domestic : 1,05,464 units (down 2%) Exports : 56,982 units (up 32%) Combined exports grew 16% YoY during the quarter, while domestic sales fell 8%, reflecting softer demand trends in the Indian market. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
an hour ago
- Business Upturn
Apollo Hospitals shares surge 4% after board approves plan to list pharmacy, digital health arms
Shares of Apollo Hospitals climbed 4% after the company announced a strategic restructuring to unlock value by spinning off its pharmacy and digital health businesses into a separate listed entity. As of 9:37 AM, the shares were trading 4.10% higher at Rs 7,539.00. The board of Apollo Hospitals and its subsidiary, Apollo HealthCo, has given in-principle approval for a composite scheme of arrangement. As per the proposal, Apollo will demerge its omni-channel pharmacy, telehealth services, and digital health business into a newly formed entity, tentatively referred to as NewCo. Following the demerger, Apollo HealthCo will be merged into NewCo. In addition, Keimed Pvt Ltd — a major pharmaceutical distributor in India — will also be brought under NewCo, creating a fully integrated pharmacy and digital healthcare platform. The company aims for the new unit to achieve ₹25,000 crore in revenue by FY27. NewCo will also acquire the remaining 74.5% stake in Apollo Medicals Pvt Ltd, which holds full ownership of Apollo Pharmacies Ltd. This move consolidates control over the retail pharmacy business. Apollo Hospitals will retain a 15% stake in the new entity. The listing of NewCo on Indian exchanges is expected within 18–21 months, subject to regulatory approvals. The restructuring is aimed at streamlining operations and boosting long-term shareholder value. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
an hour ago
- Business Upturn
Dixon Technologies shares slip 3% after Morgan Stanley downgrade stock to ‘Underweight'
By Aman Shukla Published on July 1, 2025, 09:52 IST Shares of Dixon Technologies fell 3% in early trade after global brokerage Morgan Stanley downgraded the stock to 'Underweight' and lowered its target price to ₹11,563. As of 9:51 AM, the shares were trading 2.96% lower at Rs 14,539.00. In its note, the brokerage cited concerns over increased competition in Dixon's core Electronics Manufacturing Services (EMS) segment, particularly after the Production Linked Incentive (PLI) benefits phase out. It also pointed to a likely slowdown in the company's earnings growth over the medium term. Morgan Stanley estimates that Dixon's core EMS business could see earnings growth drop by 46% during FY25–27, followed by a more moderate 18% growth rate between FY27–30. The firm believes that this slowdown could weigh on the stock's performance going forward. While the company's move into component manufacturing is seen as a positive strategic step, Morgan Stanley flagged execution challenges, noting that success in this segment hinges on securing technology partnerships, regulatory approvals, and maintaining cost efficiency. On Dixon's entry into the display fabrication space, the brokerage highlighted the deep cyclical nature of the business. It noted that such a venture would require sustained capital investment and R&D expenditure, adding another layer of complexity to the company's growth plans. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
